GLOW legal status: withdrawal leaves the warnings in place

What the current GLOW legal status record shows

GLOW’s ingredients have a regulatory record separate from any clinical decision to prescribe the blend. The Food and Drug Administration, the federal drug agency, distinguishes advisory discussion from its own final decisions ^[13]. Discussion of an ingredient does not authorize a pharmacy to use it. An advisory recommendation alone does not settle access for an individual patient.

FDA now places BPC-157, TB-500 and GHK-Cu for shots in its withdrawn-nominations table, rather than Category 2 ^[12]. That group is for ingredients that may pose serious safety risks. Its safety concerns remain beside those entries ^[12]. Category 1 is a group still under review, and its ingredients may get a short grace period. Withdrawal does not put these ingredients into Category 1 or grant permission to compound them.

Today, GLOW is part of the prescription care offered by Promise Peptides at mypromise.com; a licensed U.S. clinician makes the individual decision and may decline the request. The service accepts U.S. patients; both the state involved and the treatment sought can restrict what it offers. A compounded GLOW drug still lacks FDA approval. A prescription still leaves the pharmacy responsible for meeting federal and state rules ^[11][12]. This page gives general facts, not medical or legal advice. It doesn’t offer any substance.

The table changed; safety clearance did not follow

On FDA's page current as of April 22, 2026, the withdrawn-nominations table lists BPC-157, the thymosin beta-4 fragment known as TB-500, and GHK-Cu for injectable routes outside Category 2. FDA retains the associated safety concerns. The page supplies no date for when those ingredients moved out of Category 2.

The posted concerns include immune reactions and peptide impurities, along with limited safety information. Withdrawal leaves these ingredients without FDA approval, Category 1 placement or permission to compound. The Section 503A bulk-substance rules and the January 2025 interim policy remain separate parts of the eligibility question.

I read a withdrawn nomination as a record entry that leaves a favorable verdict on the ingredient unestablished. It is particularly easy for a short status label to leave the remaining warnings outside the frame.

The ingredient and the route both matter

FDA's GHK-Cu safety entry specifies injectable routes. Topical Copper Tripeptide-1 comes under different rules: FDA’s cosmetics page explains that cosmetics are regulated but not FDA-approved before sale. A skin ingredient's presence in cosmetics does not establish an injectable drug's eligibility.

The bulk-substance framework distinguishes patient-specific compounding under Section 503A from the federally registered outsourcing-facility path for larger batches. Neither path allows a pharmacy to ignore ingredient requirements. A valid prescription documents a clinical decision while leaving those requirements in force.

I think that route distinction deserves more space than a yes-or-no answer to whether GLOW is legal. A question about a cream and a question about an injection may contain the same copper-peptide name while asking about different rules.

An agenda records a discussion, not its outcome

The audited source list includes FDA’s July 23-24, 2026 advisory-committee meeting page. An agenda names substances being considered; it does not establish an agency decision or permission to compound them. The source record here does not document the outcome of that discussion.

An advisory recommendation, a final FDA action, an ingredient's pharmacy eligibility and an individual clinician's decision are different events. An outcome needs its own record; I refuse to extract one from an agenda. These are general regulatory facts, not legal or medical advice for an individual case.